3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Malignancies
1
Interventions
Cisplatin
35
pembrolizumab
29
Radiotherapy
26
Cetuximab
26
Docetaxel
17
Paclitaxel
13
Fluorouracil
13
Cyclophosphamide
12
fludarabine
11
Radiotherapy, Intensity-Modulated
11
Nivolumab
10
Carboplatin
9
atezolizumab
7
Radiation
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Bortezomib
7
fludarabine phosphate
6
Pemetrexed
5
Interleukin-2
5
Radiosurgery
4
Everolimus
4
Drug Therapy
4
Azacitidine
4
olaparib
3
motexafin gadolinium
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Head and Neck Neoplasms
×
Tiragolumab
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled